What happened
Australian tech expert Paul Conyngham used AI tools, including ChatGPT and AlphaFold, to develop a personalised mRNA cancer vaccine for his dog, Rosie. Conventional treatments for Rosie's mast cell cancer failed. Conyngham sequenced Rosie's DNA for $3,000 at UNSW, identified tumour mutations, and collaborated with UNSW's RNA Institute to create the vaccine. Rosie received her first injection in December 2025; her tumour shrunk up to 75%, improving quality of life, per Conyngham. UNSW Professor Páll Thordarson confirmed this was the first personalised cancer vaccine designed for a dog.
Why it matters
AI directly accelerates personalised medicine development, bypassing traditional R&D timelines. For biotech founders and research teams, the case illustrates a mechanism for rapid, targeted therapeutic design using existing AI models and genomic sequencing. The $3,000 sequencing cost and the ability to develop a specific vaccine highlight potential metrics for early-stage development, reducing the constraint of lengthy, expensive drug discovery.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
